Jump Financial LLC Raises Position in Fulgent Genetics, Inc. $FLGT

Jump Financial LLC lifted its stake in Fulgent Genetics, Inc. (NASDAQ:FLGT) by 267.8% in the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 93,049 shares of the company’s stock after purchasing an additional 67,749 shares during the quarter. Jump Financial LLC owned about 0.31% of Fulgent Genetics worth $1,573,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Hsbc Holdings PLC lifted its position in Fulgent Genetics by 8.5% in the fourth quarter. Hsbc Holdings PLC now owns 80,876 shares of the company’s stock worth $1,491,000 after buying an additional 6,317 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Fulgent Genetics by 25.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 18,665 shares of the company’s stock valued at $345,000 after acquiring an additional 3,747 shares during the period. Aquatic Capital Management LLC raised its stake in shares of Fulgent Genetics by 157.4% in the fourth quarter. Aquatic Capital Management LLC now owns 12,869 shares of the company’s stock valued at $238,000 after acquiring an additional 7,869 shares during the period. Northern Trust Corp lifted its holdings in shares of Fulgent Genetics by 5.8% in the 4th quarter. Northern Trust Corp now owns 225,362 shares of the company’s stock worth $4,162,000 after acquiring an additional 12,291 shares during the last quarter. Finally, Almitas Capital LLC purchased a new position in shares of Fulgent Genetics during the 4th quarter worth about $296,000. Institutional investors own 48.06% of the company’s stock.

Fulgent Genetics Stock Performance

Shares of NASDAQ:FLGT opened at $22.03 on Friday. The firm’s 50 day simple moving average is $19.75 and its 200-day simple moving average is $18.90. Fulgent Genetics, Inc. has a one year low of $14.57 and a one year high of $23.56. The firm has a market cap of $674.34 million, a PE ratio of -13.27 and a beta of 0.83.

Fulgent Genetics (NASDAQ:FLGT) last announced its quarterly earnings data on Friday, August 1st. The company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.30. The company had revenue of $81.80 million for the quarter, compared to analysts’ expectations of $76.21 million. Fulgent Genetics had a negative return on equity of 2.26% and a negative net margin of 16.83%.Fulgent Genetics’s revenue was up 15.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.15 earnings per share. Fulgent Genetics has set its FY 2025 guidance at -0.350–0.350 EPS. Equities research analysts predict that Fulgent Genetics, Inc. will post -0.85 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Piper Sandler set a $21.00 price objective on shares of Fulgent Genetics and gave the stock a “neutral” rating in a research report on Monday, August 4th. UBS Group upgraded Fulgent Genetics from a “neutral” rating to a “buy” rating and increased their price target for the stock from $20.00 to $30.00 in a report on Tuesday, August 5th. Finally, Raymond James Financial reissued an “outperform” rating and set a $25.00 price target (up from $24.00) on shares of Fulgent Genetics in a research note on Monday, May 5th. Two research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $25.33.

Insider Activity at Fulgent Genetics

In related news, COO Jian Xie sold 1,199 shares of Fulgent Genetics stock in a transaction dated Wednesday, August 27th. The stock was sold at an average price of $21.48, for a total value of $25,754.52. Following the completion of the sale, the chief operating officer directly owned 365,249 shares in the company, valued at $7,845,548.52. The trade was a 0.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders sold a total of 3,386 shares of company stock worth $72,756 in the last 90 days. Company insiders own 31.76% of the company’s stock.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.